|
Dear
HealthDesigns Member,
In
this issue:
|
|
|
|
|
Dementia
Risk Rises With Hormone Replacement Therapy Use
|
|
|
|
|
BETHESDA,
MD (Medical Newswire) Older women taking combination hormone therapy had twice
the rate of dementia (can include forgetfulness, impairment in abstract
thinking, impaired judgment, other disturbances of higher cortical function,
personality change)-- including Alzheimer’s disease -- as women who did not
take the medication, suggests a new study.
The
research, which appears in the latest Journal
of the American Medical Association, notes heightened
risk of developing dementia in a study of women 65 and older taking Prempro, a
form of estrogen-plus-progestin hormone therapy.
The
study also found that the combination therapy did not protect against the
development of Mild Cognitive Impairment, a form of cognitive decline less
severe than dementia.
To
find an alternative nutritional approach to supporting the needs of the female
organ systems during this phase of your life click on this link: http://www.healthdesigns.com/MenopauseTest.html
If you have questions about this news or would like to “Ask the Doc” a
question click on this link: http://www.healthdesigns.com/AsktheDoc.html
|
| Research
Summary: EstroFactors™ |
|
EstroFactors
now on sale at www.healthdesigns.com
- click
here. |
|
A Natural Alternative for Women
While up to 75% to 85% of
postmenopausal women in the U.S. experience
undesirable hormone-related symptoms, as
little as 10% to 30% may currently use common
medical therapies for relief. This may be due
to the recent controversies focusing on
traditional medical approaches. Women are
increasingly turning to natural alternatives
to relieve common complaints such as:
| √ Hot
flushes |
√ Night
sweats |
√ Mild
mood swings |
EstroFactors
provides a natural, safe, and effective
approach to relieving these common menopausal
symptoms. Due to its effects on estrogen
balance, EstroFactors may also help relieve
common symptoms associated with premenstrual
syndrome (PMS) including:
| √ Cramping |
√ Occasional
irritability |
√ Breast
tenderness |
|
|
|
|
The
EstroFactors Advantage
Whereas many
natural alternatives offer only single
nutrient/single pathway hormonal
support, EstroFactors
addresses multiple aspects:
- Modulates
estrogenic activity.
EstroFactors
features selective estrogen
receptor modulators (SERMs)—compounds
that exert estrogenic/antiestrogenic
activity. By occupying estrogen
receptor sites and modulating
estrogen activity, SERMs may
promote a healthy estrogen
balance. 1
Key
nutrients: Mixed isoflavones and
resveratrol.
|
|
|
|
- Modulates
estrogen metabolism.
EstroFactors promotes the preferred
pathways of estrogen metabolism, favoring
the conversion of estrone to
2-hydroxyestrone (2-OHE) over 16α-hydroxyestrone
(16α-OHE). Research suggests that an
estrogen metabolite balance that favors
2-OHE is beneficial to breast tissue
health.2,3
Key
nutrients: Mixed isoflavones and rosemary
extract.
- Promotes
healthy estrogen detoxification.
EstroFactors
promotes the detoxification and excretion
of catechol estrogens via methylation.
Catechol estrogens are metabolites that
readily oxidize and can negatively impact
cells, such as those found in the breast.
By supporting their methylation,
EstroFactors may help render these
metabolites less harmful, thereby
providing support for healthy breast
tissue.4
Key
nutrients: Folate† (as
L-5-methyl tetrahydrofolate‡,
5-formyl tetrahydrofolate, and folic
acid), trimethylglycine, and vitamins B6
and B12.
†
Featuring ActiFolate™, a proprietary
blend of active folates.
‡ As Metafolin® U.S. Patent
Nos. 5,997,915; 6,254,904.
- Supports
healthy aromatase activity.
EstroFactors may
modulate estrogen levels via the
inhibition of aromatase, an enzyme that
converts androgens into estrogens.
Aromatase is located in adipose cells,
including those of breast tissue, and its
inhibition may modulate the cell-proliferative
effects of estrogen.5
Key
nutrient: Chrysin.
|
|
The
Metagenics Difference
While other companies
may solely rely on third party research,
Metagenics is the only company in its niche
with a facility dedicated to determining
clinical outcomes. At the Functional Medicine
Research Center (FMRC)—the research arm of
Metagenics—the staff of scientists and
health professionals conducts trials to
evaluate the effectiveness of natural
alternatives.
Clinically
Proven Benefits of EstroFactors:
- Supports a healthy
mood and promotes emotional well-being.
- Clinically shown to
reduce hot flashes by an average of 46%.
- Promotes the
conversion of estrone to 2-OHE over 16α-OHE,
which is important for maintaining healthy
breast tissue.
|
|
RESEARCH
SPOTLIGHT
|
Clinical
Trial on the Effects of EstroFactors
in Postmenopausal Women:
A Summary of Findings
|
In
a 12-week clinical trial, 25
postmenopausal women suffering
from severe hot flushes and/or
night sweats were instructed
to take EstroFactors (3
tablets per day with a meal).
Participants’ symptoms were
measured by a standardized
questionnaire. Laboratory
tests included measurements of
estrogen metabolites (2-OHE
and 16α-OHE). Following
the treatment period,
participants reported a 46%
average decrease in hot
flushes, from an average of
9.7 per day to 5.2 per day.
Similar improvements were
reported in overall quality of
life, as related to mild mood
changes and emotional
well-being. Additionally,
2-OHE levels significantly
increased, whereas 16α-OHE
levels decreased, suggesting
that EstroFactors supports
breast tissue health. These
findings corroborate the
ability of EstroFactors to
relieve multiple menopausal
symptoms, while simultaneously
supporting the health of
hormone-sensitive tissues.
|
 |
Lukaczer
D, Darland G, Tripp M, et al.
Clinical effects of a
proprietary nutritional
supplement in postmenopausal
women: a pilot trial. Advanced
Nutrition Publications, Inc.
2002;113:1-9. |
|
|
| |
|
Additional
articles cited:
- Brzezinski A, Debi A. Phytoestrogens:
the “natural” selective estrogen
receptor modulators? Obstet Gynecol
Reprod Biol 1999;85(1):47-51.
- Lu LJ, Cree M, Josyula S, et al.
Increased urinary excretion of
2-hydroxyestrone but not 16α-hydroxyestrone
in premenopausal women during a soya diet
containing isoflavones. Cancer Res
2000;60(5):1299-305.
- Muti P, Bradlow HL, Micheli A, et al.
Estrogen metabolism and risk of breast
cancer: a prospective study of the 2:16α-hydroxyestrone
ratio in premenopausal and postmenopausal
women. Epidemiology
2000;11(6):635-40.
- Butterworth M, Lau SS, Monks TJ. 17
β-estradiol metabolism by hamster
hepatic microsomes. Implications for the
catechol-O-methyl transferase-mediated
detoxication of catechol estrogens. Drug
Metab Dispos 1996;24(5):588-94.
- Jeong HJ, Shin YG, Kim IH, et al.
Inhibition of aromatase activity by
flavonoids. Arch Pharm Res
1999;22(3):309-12.
|
|
EstroFactors
now on sale at www.healthdesigns.com
- click
here.
|
These
statements have not been evaluated by the Food
and Drug Administration.
These products are not
intended to diagnose, treat, cure, or prevent
any disease.
|
|
|
|